Skip to main navigation menu Skip to main content Skip to site footer
×
Español (España) | English
Editorial
Home
Indexing
Review

Survival of patients diagnosed with Burkitt lymphoma in people living with the human immunodeficiency virus.

By
Bryan Esteban Maldonado Piña ,
Bryan Esteban Maldonado Piña

Universidad Católica de Cuenca, Carrera de Medicina- Campus Cuenca, Cuenca, Ecuador

Search this author on:

PubMed | Google Scholar
Juan Antonio Coyago Íñiguez ,
Juan Antonio Coyago Íñiguez

Universidad Católica de Cuenca, Carrera de Medicina- Campus Cuenca, Cuenca, Ecuador

Search this author on:

PubMed | Google Scholar
Jery Estefano Maldonado Piña ,
Jery Estefano Maldonado Piña

Sociedad de Lucha contra el Cáncer, Guayaquil, Ecuador

Search this author on:

PubMed | Google Scholar
Daniela Lorena Barros Narváez ,
Daniela Lorena Barros Narváez

Universidad Católica de Cuenca, Carrera de Medicina- Campus Cuenca, Cuenca, Ecuador

Search this author on:

PubMed | Google Scholar

Abstract

Introduction: Burkitt type lymphoma (BL) is one of the most common neoplasms in patients with HIV due to the immune compromise they present. BL patients who live with human immunodeficiency virus (HIV) have a survival rate of approximately 69% two years after diagnosis. However, other authors mention that survival is only 50%, in patients on antiretroviral treatment (ART) and chemotherapy, two years after diagnosis. BL occurs between 50% to 70% more in HIV-positive people and a low CD4 lymphocytes count increases the predisposition to develop BL. Chemotherapy is the method of choice for the treatment of Burkitt-type lymphoma in HIV-positive patients.

Objective: Determine the survival of patients diagnosed with Burkitt lymphoma in people living with human immunodeficiency virus

Methodology: Narrative bibliographic review. For the bibliographic search, information collected from the following databases was used: PubMed in conjunction with the application of Boolean operators: AND, OR, NOT; and with the help of search MeSH terms like, “Burkitt lymphoma”, AND “HIV” AND “Treatment”.

Results: Patients have a higher incidence of Burkitt-type lymphoma due to their immunosuppression, which is why it is important that they correctly adhere to antiretroviral treatment and chemotherapy, since the survival of these patients can be between 45% and 50%, two years after de diagnosis

Keywords: Burkitt Lymphoma, Treatment, HIV

How to Cite

1.
Maldonado Piña BE, Coyago Íñiguez JA, Maldonado Piña JE, Barros Narváez DL. Survival of patients diagnosed with Burkitt lymphoma in people living with the human immunodeficiency virus. Salud, Ciencia y Tecnología [Internet]. 2022 Dec. 30 [cited 2024 Mar. 28];2:179. Available from: https://revista.saludcyt.ar/ojs/index.php/sct/article/view/179

The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.

Article metrics

Google scholar: See link

Metrics

Metrics Loading ...

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.